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Thiazolidinediones: anti-diabetic drugs to treat 
cancer?
Thiazolidinediones (TZDs) are potent insulin 
sensitizers used to prevent and treat type 2 diabetes 
[1]. Widely-used in the early 2000’, pharmacological 
treatments with these compounds have been drastically 
reduced due to adverse effects, like weight gain, 
hepatotoxicity, and congestive heart failure [1, 2]. 
Nevertheless, two members of this family of compounds, 
rosiglitazone (Avandia) and pioglitazone (Actos), are still 
approved for the treatment of type 2 diabetes in selected 
patients and under restricted conditions.
Besides treatment of diabetes, TZDs have been 
proposed as a therapeutic option for cancer. This was 
initially based on the observation that the nuclear receptor 
PPARγ -the best characterized molecular target of TZDs- 
exhibits anti-cancer properties. PPARγ is involved in 
the regulation of several conditions that are key for 
controlling tumor growth, like cell proliferation, cell 
survival, cell differentiation, and inflammation [2, 3]. 
Moreover, genetic evidence shows that loss of PPARγ 
function predisposes to colon, breast, ovary and skin 
cancers [4]. Finally numerous studies have reported anti-
tumoral effects of PPARγ activation both in vitro and in in 
vivo mouse models, possibly also in humans [4]. Despite 
anti-cancer properties reported in many cancer cell types, 
clinical trials involving TZDs and activation of PPARγ, 
which were performed over the past 15 years have been 
disappointing, showing little therapeutic efficacy [2].
Undesirable pro-tumorigenic actions of 
rosiglitazone in metastatic human melanoma cells.
Skin melanoma, an aggressive malignant 
neoplasm of melanocytes, is the most dangerous form 
of skin cancer. Although it represents only 4% of all 
skin cancers, it is currently responsible for 80% of skin 
cancer-related deaths. Cancer research has taught us that 
melanoma require multiple therapeutic approaches. The 
search for treatments against melanoma is therefore still 
active, despite the recent breakthrough of immuno- and 
molecularly targeted therapies [5]. 
Several studies conducted over the past 20 years 
supported the use of TZDs and of PPARγ activation as a 
therapeutic option to treat melanoma [6]. However, these 
studies showed anti-cancer effects on the malignant cells 
(Figure 1), while they neglected the role played by non-
malignant cells of a tumor microenvironment. Recently, 
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Figure 1: The Janus face of rosiglitazone in melanoma. On the one hand, rosiglitazone shows cell-autonomous anti-cancer actions 
(in blue) in melanoma cells, by preventing proliferation and promoting apoptosis [6]. On the other hand, rosiglitazone shows pro-cancer 
actions (in red). These include cell-autonomous impact on macrophages [6], as well as paracrine effects on fibroblasts, endothelial cells 
and tumor associated macrophages [7]. Of note, while the metabolic actions of rosiglitazone are clearly mediated by PPARγ, its actions on 
cancer cells can only partially be explained by PPARγ activation [2]. The figure was inspired by discussion with Dr Thanh Nhan N’Guyen.
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a study of TZDs impacts extended beyond the melanoma 
cell itself, and identified a new pro-tumorigenic paracrine 
action of rosiglitazone (RGZ) [7]. This pro-tumorigenic 
action of RGZ involves increased secretion of cytokines, 
chemokines and angiogenic factors by a subset of 
human melanoma cells, in turn activating non-malignant 
fibroblasts, endothelial cells and macrophages in a tumor-
friendly way (Figure 1). In mice, tumors derived from 
human melanoma cells and exposed to RZG exhibited 
accelerated development, and increased inflammation 
and angiogenesis. In this model of melanoma, RGZ 
pro-tumorigenic action prevailed over its anti-cancer 
action [7]. In addition, in line with these results, RGZ 
retained this pro-tumorigenic effect on human melanoma 
cells exposed to Vemurafenib, a recently approved 
pharmacological treatment of melanoma targeting the 
BRAF mutant BRAFV600E [8] [Pich et al, unpublished 
results]. In these melanoma cells, RGZ partially prevented 
Vemurafenib from inhibiting proliferation and interleukins 
secretion, thereby reducing Vemurafenib efficacy.
Collectively, these data suggest that adverse 
consequences may result from exposing patients with 
existing melanoma to RGZ, and potentially to other 
PPARγ agonists. Finally, although focusing on melanoma, 
the study by Pich and collaborators suggests that RGZ 
may have similar undesirable impacts in other pre-existing 
tumors, like non-melanoma skin cancers and bladder 
cancers [7]. 
Thiazolidinediones as an option to treat cancer: 
balancing pro-tumorigenic and anti-cancer effects.
The vast majority of studies conducted on cohorts 
of diabetic patients with no pre-existing tumors report 
overall preventive benefits of TZDs, with the exception 
of pioglitazone, which was suspected to slightly increase 
the risk of bladder cancers, non-Hodgkin lymphoma and 
melanoma [2, 9]. For existing tumors, investigation of 
TZDs as a therapeutic option led to contradictory findings, 
showing pro-tumorigenic effects on the one hand and 
anti-cancer effects on the other hand. These contrasting 
results seem to result from a combination of complex 
PPARγ-dependent or -independent impacts, context- 
and compound- specific actions and, as shown in [7], 
pro-tumorigenic effects on the tumor microenvironment 
opposing the anti-cancer effects observed on the malignant 
cells (Figure 1). Recent progress in -omics and single cell 
techniques will likely allow for a better understanding of 
how the various cells types in a tumor respond to TZDs. 
TZDs complex and contrasting actions make it 
impossible to generalize the impact of pharmacological 
treatment in regard to cancer development. Moreover, 
they partially explain why promising in vitro studies have 
not been translated into convincing clinical trials. Besides 
TZDs, the search for novel PPARγ agonists is still active 
[10] and their impact on cancer cells is still questioned. 
Finding PPARγ agonists that retain anti-cancer activities 
but lack pro-tumorigenic properties would be potential 
therapeutic options for cancer treatment.
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